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Synopsis 20 
Topical ophthalmic drugs cause shifts in pupil center that do not match those produced by 21 
natural changes in pupil size, and in the cases of phenylephrine and tropicamide the shifts 22 
follow a different time course than the pupil size changes. 23 
 24 
  25 
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Purpose: To investigate the time course of pupil centration following application of common 26 
topical ocular drugs. 27 
Method: Single drops of each of 2.5% phenylephrine hydrochloride, 1% tropicamide, and 28 
2% pilocarpine hydrochloride were applied on different days to the right eyes of 12 29 
participants.  Anterior eye images were captured, at 5 minute intervals for an hour, using an 30 
infrared-sensitive camera. The images were analysed to determine pupil diameter and pupil 31 
center, the latter with respect to the limbal center. As a control, natural pupil size and pupil 32 
center were determined under different illuminances. 33 
Results: Pupil centers of natural pupils shifted temporally as pupils dilated. At common pupil 34 
sizes, drug-induced pupil centers were different from natural pupil centers. Phenylephrine 35 
produced a center shift in the nasal and inferior directions that peaked after a mean 30 36 
minutes, while dilation was continuing up to 60 minutes. Tropicamide produced transient 37 
center shifts in the nasal and inferior directions that peaked at about 10 minutes before 38 
reducing towards baseline values, while dilation reached a peak at about 25 minutes. 39 
Pilocarpine produced a small sustained superior shift that, like constriction, reached a peak 40 
after about 25 minutes. 41 
Conclusion: Application of topical ophthalmic drugs cause shifts in pupil center that do not 42 
match those produced by natural changes in pupil size, and that in the cases of phenylephrine 43 
and tropicamide follow a different time course than the pupil size changes. 44 
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INTRODUCTION 48 
Pupil size is influenced by illuminance and by ophthalmic drugs that act on the sympathetic 49 
and parasympathetic nervous systems. Accompanying changes in pupil size are pupil center 50 
shifts. Consideration of the latter is important as pupil shifts affect aberrations,1, 2 particularly 51 
if wavefront guided refractive surgery is undertaken at a different drug state than that under 52 
which the aberrations are measured.3 53 
There is a temporal or infero-temporal pupil center shift as the pupil dilates in response 54 
to lowered luminance.2, 4-11 Typically this is of the order of 0.1 mm, but with considerable 55 
variation and with some individuals having shifts of 0.5 mm to 0.6 mm.  56 
The sympathetic α1-agonist phenylephrine hydrochloride causes pupil dilation. Under 57 
mesopic lighting conditions, Porter et al.3 found mean shifts of 0.20±0.13 mm temporally and 58 
0.16±0.14 mm inferiorly, with the vast majority of participants showing shifts in these 59 
directions. 60 
The anticholinergic cyclopentolate hydrochloride causes cycloplegia and pupil dilation. 61 
Accompanying these are pupil center shifts of considerable inter-individual variation, but 62 
with small group means in the horizontal and vertical directions of 0.10 mm or less6, 9, 12.For 63 
example, under photopic lighting conditions, Walsh6 found pupil shifts of  0.03 ± 0.15 mm 64 
(mean ± standard deviation)  temporally and 0.02±0.14 mm superiorly. 65 
The pupil center shifts in the previous studies were determined when pupil dilation 66 
was considered to be complete. We hypothesise that the time course of pupil center shift is 67 
similar to that of changes in pupil size. To increase our knowledge of actions of topically 68 
applied ophthalmic drugs, we have investigated the time course of phenylephrine 2.5%, 69 
tropicamide 1% and also the cholinergic agonist pilocarpine hydrochloride 2% that constricts 70 
the pupil and stimulates accommodation.  71 
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METHODOLOGY 72 
The study was conducted in compliance with the tenets of the Declaration of Helsinki and 73 
was approved by the University’s Human Research Ethics Committee. There were 12 74 
participants, with mean age 30 ± 12 years and age range 21-61 years. They were in good 75 
general and ocular health and had been screened for contraindication to the use of the drugs. 76 
Each participant attended three sessions, separated by at least 48 hours. They were 77 
advised to not drink caffeine drinks for at least three hours prior to a session. The drug to be 78 
used for a session for each participant was randomly allocated using Microsoft Excel’s 79 
random sequence generator. 80 
Pupil images were captured with the high resolution infrared-sensitive camera of a 81 
Complete Ophthalmic Assessment System – High Definition (COAS-HD) Hartmann-Shack 82 
aberrometer (Wavefront Sciences, Albuquerque, New Mexico). At the first session and 83 
before drug instillation, images were captured under different illuminances at the eye, by 84 
manipulating room lighting, of between 0.013 and 45 lux as measured with an ILT 1700 85 
radiometer (International Light Technologies, Peabody, Massachusetts). During each pupil 86 
image capture, the participants looked at the central red source of the aberrometer without 87 
blinking while resting their forehead and chin against the head rest. Pupil images were 88 
captured 1 minute and 5 minutes after a drug was instilled, and every five minutes thereafter 89 
for 60 minutes. Three images were taken as rapidly as possible at each time point. 90 
For phenylephrine and tropicamide, a 26 lux level was used to induce an initially small 91 
pupil size. For pilocarpine, a 0.013 lux level was used to induce an initially large pupil size, 92 
with a five-minute dark adaptation period before instillation. One drop of a drug was instilled 93 
into the infero-temporal fornix of the right eye, with the participant’s eye looking upwards 94 
and inwards (Figure 1 left). 95 
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For three participants, measurements were repeated twice with tropicamide. The second 96 
session was the same as described above. For the third session, because of interest in how the 97 
position of drug instillation might affect results, the drug was instilled in the superior-nasal 98 
fornix while the participant was standing up, but bending over so that the head was upside-99 
down. The participant looked outwards and upwards (towards the chin) and stayed that way 100 
until thirty seconds after instillation (Figure 1 right). For these additional sessions, images 101 
were taken every 2.5 minutes after instillation for 30 minutes and then every 5 minutes for 102 
another 30 minutes. 103 
The pupil images were analyzed using a custom-written computer program. Each image 104 
was displayed on the computer monitor and the computer’s mouse was used to fit an ellipse 105 
manually to both limbus and pupil margins (Figure 2). The program determined pupil 106 
diameter and (x, y) co-ordinates of the pupil center. For positive x and y, the pupil center was 107 
nasal and superior to the limbal center. 108 
To establish repeatability, two randomly selected images were analyzed for each of four 109 
participants. Each image was analyzed for pupil centration three times and the standard 110 
deviations were determined. Across the eight images, the mean of the standard deviations 111 
was 0.04 ± 0.02mm for both horizontal and vertical pupil positions, thus indicating that 112 
differences of 0.05 mm between times for an individual can be considered to be of 113 
significance. 114 
One-way repeated measures ANOVAs were used to determine significance of time after 115 
drug instillation on horizontal and vertical pupil center components. Where significant, paired 116 
t-tests were used to determine at which time-points the mean pupil size and pupil center were 117 
significantly different from those at baseline. Significance criterion was set at 0.05, but as 118 
there were 13 time points to compare with baseline for each drug, a Bonferroni correction 119 
was also applied to set a second significance criterion was set at < 0.05/13 or 0.004. As only 120 
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29/117 pairwise comparisons did not have normally distributed differences according to the 121 
Kolmogorov-Smirnov test, normality was assumed for all comparisons.  122 
To allow the comparison of pupil centration under natural and pharmacological 123 
conditions at any pupil diameter, fits were made for natural pupil centration as a function of 124 
pupil diameter. The quadratic function was used if the second order co-efficient was 125 
significant, otherwise the linear fit was used if the first order coefficient was significant. 126 
 127 
RESULTS 128 
Figure 3 shows the group horizontal and vertical components of pupil center as a function of 129 
natural pupil diameter. For the horizontal component, a quadratic regression was used as all 130 
its coefficients were significantly different from zero (p<0.01), but for the vertical component 131 
neither first order nor second order co-efficients were significant. Maximum mean horizontal 132 
shift over the range of pupil sizes was 0.12mm. The natural pupil size range was insufficient 133 
to obtain natural pupil center locations corresponding to all time points with interpolation in 134 
Figures 4-7, mainly for tropicamide (Figures 5, 7).  135 
Figure 4 shows the group time course of pupil diameter and centration for 136 
phenylephrine. Dilation does not seem to have been completed by 60 minutes. Pupil center 137 
shifts in the nasal direction were significant from 15 minutes onwards. We noted greater 138 
elongation vertically than horizontally within the first 15 minutes in many participants; 139 
sometimes this was more peared-shaped than elliptical. Shifts in the inferior direction were 140 
significant from 25 minutes onwards, although not with a Bonferroni correction (Figure 4b). 141 
Six of the 12 participants had an infero-nasal pattern, while three had a nasal shift, two had an 142 
inferior shift and one had a superior shift. The shifts reached plateaus at about 35-40 minutes 143 
of approximately +0.20 mm and –0.18mm, and were much greater than those for natural 144 
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pupils. The maximum absolute shift of 0.30 ± 0.20 mm (mean ± standard deviation) occurred 145 
at 40 minutes. 146 
Figure 5 shows the group time course of pupil diameter and centration for tropicamide. 147 
Dilation plateaued at approximately 30 minutes. There were significant transient shifts in 148 
pupil center both nasally (10-20 minutes) and inferiorly (5-15 minutes), with respective 149 
maximums of +0.15 ± 0.12 mm and –0.20 ± 0.17 mm. Six of the 12 participants had this 150 
transient infero-nasal pattern, while three had a transient inferior shift, one had a transient 151 
nasal shift, one had a transient inferior shift and a sustained nasal shift, and one could not be 152 
categorized.  153 
Figure 6 show the group time course of pupil diameter and centration for pilocarpine. 154 
Constriction plateaus after approximately 40 minutes. Time affected pupil center significantly 155 
vertically but not horizontally. There was an indication of a small temporal shift that reached 156 
a maximum at about 10 minutes. The vertical pupil component shifted in the superior 157 
direction; the shift was significant at 20 minutes and reached a plateau at about 35 minutes, 158 
with a maximum of 0.12±0.08mm. Only 3 participants had a transient temporal shift, but 7 159 
participants had the superior shift. 160 
For tropicamide, the pupil center shifts were mainly transient, both horizontally and 161 
vertically (Figure 5b). For three participants showing transient infero-nasal shifts, repeat 162 
measurements were taken with instillation in the infero-temporal fornix so that the drug 163 
would have to diffuse upwards and inwards to reach the iris. As described in the Methods, we 164 
reversed this in a third session so that the drug would have to move downwards and outwards 165 
to reach the iris from the superior-nasal fornix (or movement was upwards for the patient’s 166 
head perspective). Each participant showed similar results across the three sessions. Figure 7 167 
shows results for one participant. The course of pupil dilation was similar for the three runs 168 
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(Figure 7a). The transient effects occurred for all three runs, but were slightly greater and 169 
lasted longer for the second and third sessions (Figure 7b).  170 
 171 
DISCUSSION 172 
Our hypothesis was that the time course of pupil center shift is similar to that of changes in 173 
pupil size. This was the case for pilocarpine which showed a sustained superior shift that was 174 
complete about the time that constriction was complete. However, the hypothesis was not 175 
supported for phenylephrine and tropicamide. While there was considerable inter-individual 176 
variation, we found an infero-temporal pupil shift with phenylephrine that was complete after 177 
40 minutes although pupil dilation was still continuing up to 60 minutes, and tropicamide 178 
showed transient infero-nasal shifts in several participants that occurred before dilation was 179 
completed at about 30 minutes. 180 
The maximum pupil shift with phenylephrine, of 0.21 ± 0.16mm temporally and 181 
0.18±0.16 mm inferiorly was similar to the 0.20±0.13 mm temporally and 0.16±0.14 mm 182 
inferiorly reported by Porter et al.3 However, we found that dilation was continuing until at 183 
least 60 minutes. Maximum dilation with phenylephrine was found in previous studies to 184 
occur at times between about 40 minutes and 70 minutes.13-18 185 
At full dilation, tropicamide showed little shift in pupil center, as has been found for 186 
cyclopentolate, its fellow anticholinergic6, 9, 12. It is not clear why the transient nasal and 187 
inferior center shifts should occur. The radial nature of the dilator fibres allows for sector 188 
effects with phenylephrine; Chang et al.14, 15 reported that the pupil elongates more vertically 189 
than horizontally, as was found in this study within approximately the first 15 minutes in 190 
many eyes. Effects with tropicamide are unexpected because it acts on the annular iris 191 
sphincter muscle fibers and Chang et al.14, 15 found no changes in pupil shape with it.  Were 192 
there to be an effect according to the position of drug instillation and simple diffusion of the 193 
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drug into the eye, the inferior pupil shift was in the expected direction but the nasal direction 194 
was opposite from that expected.  195 
Wyatt & Lustgarten19 explained such effects in terms of convection flow in the eye. As 196 
well as applying phenylephrine and tropicamide to the lower temporal fornix, they applied it 197 
to the superior, inferior, nasal and temporal limbal regions of a few participants. Although 198 
participants were followed over 1 hour, most emphasis was given to the final pupil shape and 199 
location. A diagram for one participant clearly showed sector dilation with tropicamide 200 
towards the temporal application site, with gradual rounding of the pupil but with 201 
maintenance of the temporal decentration. Wyatt & Lustgarten suggested that the failure of 202 
Chang et al.14, 15 to notice sector dilation with tropicamide was that the drug was instilled too 203 
far away from the limbus: this would also explain our failure to see a change in pupil shift 204 
pattern in three participants when this drug was instilled in the superior-nasal fornix (with the 205 
head upside-down) rather than in the lower infero-temporal fornix.  206 
The results of the study have implications for combining aberration measurements and 207 
wavefront-guided corneal refractive surgery. For the completely or nearly dilated pupil, 208 
considerable mean infero-nasal shifts were obtained with phenylephrine (Figure 4b) but small 209 
mean shifts were obtained for tropicamide (Figure 5b). However, there was considerable 210 
inter-individual variation with both drugs. This indicates that either individual correction 211 
should be made if aberrations are measured over a dilated pupil but treated over an undilated 212 
pupil, or, and probably better, both aberration measurements and treatment are done over a 213 
natural pupil. 214 
Sometimes phenylephrine and tropicamide are combined in clinical practice. By 215 
averaging the effects in Figures 4b and 5b, we speculate that there would be nasal and 216 
inferior shifts that are 0.10 mm (or slightly larger) at 10-60 minutes after instillation.  217 
 218 
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CONCLUSION 219 
Application of the topical ophthalmic drugs 2.5% phenylephrine, 1% tropicamide and 2% 220 
pilocarpine cause shifts in pupil center that do not match those produced by natural changes 221 
in pupil size, and that in the cases of phenylephrine and tropicamide follow a different time 222 
course than pupil size changes. 223 
 224 
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FIGURE CAPTIONS 273 
Figure 1. (Left) drug instilled in infero-temporal fornix of right eye with the right eye looking 274 
up and inwards. (Right) drug instilled in superior-nasal fornix of right eye with the right eye 275 
looking up (towards chin) and outwards.  276 
 277 
Figure 2. Image of eye showing fitted ellipses to limbus and pupil margins. Red and green 278 
centers are the limbal center and pupil center, respectively. Pupil center position, relative to 279 
the limbus center, and pupil diameter are indicated. 280 
 281 
Figure 3. Group mean horizontal and vertical components of pupil center (relative to limbus 282 
center) as a function of mean natural pupil diameter at different lighting levels. Horizontal 283 
and vertical error bars are 95% confidence intervals of means of pupil diameter and pupil 284 
center, respectively. Fitting equations are: horizontal y =0 0.026x2 – 0.235x + 0.71; vertical y 285 
= +0.16 mm. To improve clarity, data for vertical components are shifted 0.1mm to the right. 286 
 287 
Figure 4. (a) Mean pupil diameters with phenylephrine up to 60 minutes after drug 288 
instillation; (b) mean horizontal and vertical components of pupil center over the 60 minutes. 289 
Natural pupil centers estimated from regressions in Figure 1 are shown at pupil sizes 290 
corresponding to a). Asterisks represent significant pupil center differences from that at 291 
baseline, with large asterisks corresponding to Bonferroni correction and small asterisks to no 292 
Bonferroni correction. Error bars are 95% confidence intervals of the means – note that the 293 
scale is different from those of Figures 5b, 6b and 7b. 294 
 295 
14 
 
Figure 5. (a) Mean pupil diameters with tropicamide up to 60 minutes after drug instillation; 296 
(b) mean horizontal and vertical components of pupil center over the 60 minutes – note that 297 
the scale is different from those of Figure 4b, 6b and 7b. Other details are as for Figure 4. 298 
 299 
Figure 6. (a) Mean pupil diameters with pilocarpine up to 60 minutes after drug instillation; 300 
(b) mean horizontal and vertical components of pupil center over the 60 minutes. To improve 301 
clarity, vertical components are plotted 1 minute after the true time – note that the scale is 302 
different from those for Figure 4b, 5b and 7b. Other details are as for Figure 4. 303 
 304 
Figure 7. Results for participant 1 for 3 sessions, in the third of which the drug tropicamide 305 
was instilled in the upside-down position. (a) Mean pupil diameters with tropicamide up to 60 306 
minutes after drug instillation; (b) mean horizontal and vertical components of pupil center 307 
over the 60 minutes – note that he scale is different from those for Figure 4b, 5b and 6b. Error 308 
bars have been removed for clarity. 309 
 310 
  311 
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Fig. 1 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
Fig. 2 320 
 321 
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       head upright                              head upside down
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Fig. 3 323 
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Fig. 5 326 
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Fig. 6. 329 
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Fig. 7 332 
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